Connect with us

Government

Best Penny Stocks To Buy This Week? 10 With Potential Biotech Catalysts

Are these 10 penny stocks on your watch list this week?
The post Best Penny Stocks To Buy This Week? 10 With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Published

on

We’re starting another week, and penny stocks are one of the hot topics among retail traders. But what if you knew certain things before they happened? What if you had a way to know when a company was going to present data or management would attend conferences? Well, you’re in luck because specific industries offer precisely that. Today, we’ll look at the biotech industry and some companies that have announced detail on why this week could be an important one.

Biotech stocks are some of the few which offer a glimpse into the future, in simple terms. Since many of these companies are involved with ongoing trials, they’ll update the public on the timing, and thus, the outlook of when they expect to reveal results. There are also firm dates for oversight bodies like the FDA giving the go-ahead for new phases of these trials, new applications, etc. So if you’re searching for biotech penny stocks to buy, doing a bit of research can give you a leg-up when it comes to preparing your trading strategy.

Penny Stocks To Watch

  1. Evofem Biosciences Inc. (NASDAQ:EVFM)
  2. Arbutus Biopharma Corporation (NASDAQ:ABUS)
  3. Adverum Biotechnologies Inc. (NASDAQ:ADVM)
  4. Enveric Biosciences Inc. (NASDAQ:ENVB)
  5. Aditxt Inc. (NASDAQ:ADTX)

Evofem Biosciences Inc. (NASDAQ:EVFM)

If you’ve read some of our articles on penny stocks under $1, Evofem is likely a company you’ve stumbled upon recently. It specializes in female contraception. Evofem’s portfolio also includes its first FDA-approved product, Phexxi®. The company has presented a series of abstracts all centered around the platform over the last few weeks. In addition, Evofem has also begun advancing its EVO100 platform in treating chlamydia and gonorrhea.

What To Watch With EVFM Stock This Week

This week, Evofem continues its circuit of presentations. On October 12, the company attends the LD Micro Investor Conference, and Chief Executive Officer Saundra Pelletier will also host one-on-one meetings. Furthermore, if EVFM stock is on your list, next week could also be an important week for the company. We’ll likely report on details again.

Read more: Best Penny Stocks To Buy According To Analysts & Targets Up To 290%

However, to give you some insight, the company delivers details on numerous abstracts at the American Society for Reproductive Medicine Scientific Congress on October 20, along with more information furnished at the International Federation of Gynecology and Obstetrics XXIII World Congress of Obstetrics and Gynecology.

Arbutus Biopharma Corporation (NASDAQ:ABUS)

Shares of Arbutus have been in focus over the last few weeks. The company specializes in developing treatments for chronic infections. This includes hepatitis B and even new therapies for treating coronaviruses. It would seem that the company continues to have milestone events to discuss. Last week, Arbutus presented at its first of 2 planned conferences at the Chardan Genetic Medicines Conference.

It also gave arguments on October 7, the United States Court Of Appeals For The Federal Circuit. This was in response to ongoing issues with Moderna (NASDAQ:MRNA). They are in conflict over Arbutus’s lipid formulations for nucleic acid delivery.

What To Watch With ABUS Stock This Week

This week ABUS stock will be in focus as it presents at another conference. Following last week’s events, investors may have October 13 on their calendars right now. This is when management presents at the H.C. Wainwright Hepatitis B Virus.

best penny stocks to buy this week Arbutus Biopharma Corporation ABUS stock chart

Adverum Biotechnologies Inc. (NASDAQ:ADVM)

Last week, Adverum was another one of the biotech penny stocks to watch. The company develops gene therapies with a primary focus on its lead candidate, ADVM-022. Last week, the company presented data from its 2-Year OPTIC study at the Retina Society Annual Meeting. This was specific to treating patients with wet age-related macular degeneration (AMD).

Results showed a more than 80% reduction in annualized anti-VEGF injection frequency and a robust response sustained through 2 years. What’s more, this weekend, the company delivered Phase 2 Data from its INFINITY trial targeting patients with diabetic macular edema treated with ADVM-022. Since we likely could see how the market responds once things open on Monday, it could be something to keep in mind with ADVM stock.

What To Watch With ADVM Stock This Week

That isn’t the only thing to keep track of this week, either. Adverum presents results from its Phase 1 OPTIC trial in patients with neovascular AMD treated with ADVM-022. In particular, if ADVM stock is on your list, October 11 will be the day to keep in mind. The company begins its presentation at 9:50 AM ET at the ASRS Scientific Meeting.

best penny stocks to buy this week Adverum Biotechnologies Inc. ADVM stock chart

Enveric Biosciences Inc. (NASDAQ:ENVB)

If you’ve followed the trend in “alternative” biotech stocks, Enveric could have been one that you came across recently. That’s because the company is focusing its model more on mental health. Enveric closed its acquisition of MagicMed last week, resulting in a new arm of the company explicitly addressing mental illness. The two companies will ultimately create a library of molecules such as psilocybin, N, N-dimethyltryptamine (DMT), and other molecular derivatives.

Read more: Hot Penny Stocks to Watch That You Might’ve Missed This Week

Aside from this, Enveric recently launched its PsyAI using artificial intelligence to offer predictive methodologies to identify molecules for new drug discovery from its molecular library, “Psybrary,” as it’s been dubbed.

What To Watch With ENVB Stock This Week

This week, however, it isn’t this transaction that has the market’s attention. It might also not be the 14.3% short position you might assume to be a point of focus for “short squeeze stock” traders. This week, Enveric 2 industry conferences. CEO Dr. Joseph Tucker will attend AGPs Biotech & Specialty Pharma Conference on October 13. He’ll also present at the KCSA Psychedelics Investor Conference on the same day.

best penny stocks to buy this week Enveric Biosciences ENVB stock chart

Aditxt Inc. (NASDAQ:ADTX)

Another company focused on immune function is Aditxt. Its monitoring technology provides personalized information on each user’s immune system. Right now, the company’s technology is in pre-clinical stages, initially being designed to address the rejection of transplanted organs and autoimmune diseases and allergies.

Read more: Top Tech Penny Stocks to Buy Right Now? 3 to Watch

One of the more recent catalysts is its asset purchases from AiPharma. Why was this such a big event? These assets include a treatment called Avigan. It has received full marketing authorization or emergency use authorization in several markets for treating COVID-19. These markets include Mexico, India, Malaysia, Thailand, and Indonesia. In the UK, UAE, Greece, Hungary, and Saudi Arabia, Avigan has received the go-ahead to sell under compassionate use programs. Keep in mind that this is in addition to Aditxt’s previously launched AditxtScore COVID-19 test.

What To Watch With ADTX Stock This Week

Following a binding agreement last week, Aditxt could be in focus again in the week ahead. That’s because the company presents at the LD Micro Main Event on Wednesday. CEO Amro Albanna will also participate in 1 on 1 meetings with investors and analysts.

best penny stocks to buy this week Aditxt Inc. ADTX stock chart

Penny Stocks This Week

There are plenty of other companies set for industry presentations this week and conference participation. This is just a handful of the ones which have gained momentum in recent sessions. Looking for more penny stocks to watch this week with potential catalysts? Here’s a list of a few more names to know and dates to keep in mind:

Clearside Biomedical (NASDAQ:CLSD) – October 9 & 11

Data from REGENXBIO’s Phase II ALTITUDE® trial in patients with diabetic retinopathy treated with RGX-314 will be presented on October 9 and 11. REGENXBIO has licensed certain exclusive rights to the SCS Microinjector® from Clearside Biomedical, Inc. to deliver gene therapy treatments.

Lipocine Inc. (NASDAQ:LPCN) – October 12

The company presents at the HC Wainwright NASH Investor Conference on October 12th. Lipocine has focused on advancing its TLANDO platform for testosterone replacement therapy. A New Drug Application was resubmitted and affirmed by the FDA last month.

Hepion Pharmaceuticals (NASDAQ:HEPA) – October 12

Hepion follows along with Lipocine as management will present at the HC Wainwright NASH Conference. Hepion’s lead candidate CRV431 is under development in clinical phases for treating NASH.

Tonix Pharmaceuticals (NASDAQ:TNXP) – October 13

This Wednesday, Tonix participates at the AGP Biotech & Specialty Pharma Conference. Management will be involved with a panel discussion about long COVID & COVID variants. Tonix is developing a portfolio of immunology treatments, including a COVID-19 platform for treating COVID, Long COVID and detect functional T cell immunity to COVID.

Daré Bioscience (NASDAQ:DARE) – October 14

This week Daré participates in a panel discussion at the DTC Perspectives Xpectives Health Summit on Thursday. The panel focuses on women’s health. Daré specializes in developing a portfolio of therapies and treatment options for contraception, fertility, and women’s health, in general.

The post Best Penny Stocks To Buy This Week? 10 With Potential Biotech Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Read More

Continue Reading

Government

Low Iron Levels In Blood Could Trigger Long COVID: Study

Low Iron Levels In Blood Could Trigger Long COVID: Study

Authored by Amie Dahnke via The Epoch Times (emphasis ours),

People with inadequate…

Published

on

Low Iron Levels In Blood Could Trigger Long COVID: Study

Authored by Amie Dahnke via The Epoch Times (emphasis ours),

People with inadequate iron levels in their blood due to a COVID-19 infection could be at greater risk of long COVID.

(Shutterstock)

A new study indicates that problems with iron levels in the bloodstream likely trigger chronic inflammation and other conditions associated with the post-COVID phenomenon. The findings, published on March 1 in Nature Immunology, could offer new ways to treat or prevent the condition.

Long COVID Patients Have Low Iron Levels

Researchers at the University of Cambridge pinpointed low iron as a potential link to long-COVID symptoms thanks to a study they initiated shortly after the start of the pandemic. They recruited people who tested positive for the virus to provide blood samples for analysis over a year, which allowed the researchers to look for post-infection changes in the blood. The researchers looked at 214 samples and found that 45 percent of patients reported symptoms of long COVID that lasted between three and 10 months.

In analyzing the blood samples, the research team noticed that people experiencing long COVID had low iron levels, contributing to anemia and low red blood cell production, just two weeks after they were diagnosed with COVID-19. This was true for patients regardless of age, sex, or the initial severity of their infection.

According to one of the study co-authors, the removal of iron from the bloodstream is a natural process and defense mechanism of the body.

But it can jeopardize a person’s recovery.

When the body has an infection, it responds by removing iron from the bloodstream. This protects us from potentially lethal bacteria that capture the iron in the bloodstream and grow rapidly. It’s an evolutionary response that redistributes iron in the body, and the blood plasma becomes an iron desert,” University of Oxford professor Hal Drakesmith said in a press release. “However, if this goes on for a long time, there is less iron for red blood cells, so oxygen is transported less efficiently affecting metabolism and energy production, and for white blood cells, which need iron to work properly. The protective mechanism ends up becoming a problem.”

The research team believes that consistently low iron levels could explain why individuals with long COVID continue to experience fatigue and difficulty exercising. As such, the researchers suggested iron supplementation to help regulate and prevent the often debilitating symptoms associated with long COVID.

It isn’t necessarily the case that individuals don’t have enough iron in their body, it’s just that it’s trapped in the wrong place,” Aimee Hanson, a postdoctoral researcher at the University of Cambridge who worked on the study, said in the press release. “What we need is a way to remobilize the iron and pull it back into the bloodstream, where it becomes more useful to the red blood cells.”

The research team pointed out that iron supplementation isn’t always straightforward. Achieving the right level of iron varies from person to person. Too much iron can cause stomach issues, ranging from constipation, nausea, and abdominal pain to gastritis and gastric lesions.

1 in 5 Still Affected by Long COVID

COVID-19 has affected nearly 40 percent of Americans, with one in five of those still suffering from symptoms of long COVID, according to the U.S. Centers for Disease Control and Prevention (CDC). Long COVID is marked by health issues that continue at least four weeks after an individual was initially diagnosed with COVID-19. Symptoms can last for days, weeks, months, or years and may include fatigue, cough or chest pain, headache, brain fog, depression or anxiety, digestive issues, and joint or muscle pain.

Tyler Durden Sat, 03/09/2024 - 12:50

Read More

Continue Reading

Government

Walmart joins Costco in sharing key pricing news

The massive retailers have both shared information that some retailers keep very close to the vest.

Published

on

As we head toward a presidential election, the presumed candidates for both parties will look for issues that rally undecided voters. 

The economy will be a key issue, with Democrats pointing to job creation and lowering prices while Republicans will cite the layoffs at Big Tech companies, high housing prices, and of course, sticky inflation.

The covid pandemic created a perfect storm for inflation and higher prices. It became harder to get many items because people getting sick slowed down, or even stopped, production at some factories.

Related: Popular mall retailer shuts down abruptly after bankruptcy filing

It was also a period where demand increased while shipping, trucking and delivery systems were all strained or thrown out of whack. The combination led to product shortages and higher prices.

You might have gone to the grocery store and not been able to buy your favorite paper towel brand or find toilet paper at all. That happened partly because of the supply chain and partly due to increased demand, but at the end of the day, it led to higher prices, which some consumers blamed on President Joe Biden's administration.

Biden, of course, was blamed for the price increases, but as inflation has dropped and grocery prices have fallen, few companies have been up front about it. That's probably not a political choice in most cases. Instead, some companies have chosen to lower prices more slowly than they raised them.

However, two major retailers, Walmart (WMT) and Costco, have been very honest about inflation. Walmart Chief Executive Doug McMillon's most recent comments validate what Biden's administration has been saying about the state of the economy. And they contrast with the economic picture being painted by Republicans who support their presumptive nominee, Donald Trump.

Walmart has seen inflation drop in many key areas.

Image source: Joe Raedle/Getty Images

Walmart sees lower prices

McMillon does not talk about lower prices to make a political statement. He's communicating with customers and potential customers through the analysts who cover the company's quarterly-earnings calls.

During Walmart's fiscal-fourth-quarter-earnings call, McMillon was clear that prices are going down.

"I'm excited about the omnichannel net promoter score trends the team is driving. Across countries, we continue to see a customer that's resilient but looking for value. As always, we're working hard to deliver that for them, including through our rollbacks on food pricing in Walmart U.S. Those were up significantly in Q4 versus last year, following a big increase in Q3," he said.

He was specific about where the chain has seen prices go down.

"Our general merchandise prices are lower than a year ago and even two years ago in some categories, which means our customers are finding value in areas like apparel and hard lines," he said. "In food, prices are lower than a year ago in places like eggs, apples, and deli snacks, but higher in other places like asparagus and blackberries."

McMillon said that in other areas prices were still up but have been falling.

"Dry grocery and consumables categories like paper goods and cleaning supplies are up mid-single digits versus last year and high teens versus two years ago. Private-brand penetration is up in many of the countries where we operate, including the United States," he said.

Costco sees almost no inflation impact

McMillon avoided the word inflation in his comments. Costco  (COST)  Chief Financial Officer Richard Galanti, who steps down on March 15, has been very transparent on the topic.

The CFO commented on inflation during his company's fiscal-first-quarter-earnings call.

"Most recently, in the last fourth-quarter discussion, we had estimated that year-over-year inflation was in the 1% to 2% range. Our estimate for the quarter just ended, that inflation was in the 0% to 1% range," he said.

Galanti made clear that inflation (and even deflation) varied by category.

"A bigger deflation in some big and bulky items like furniture sets due to lower freight costs year over year, as well as on things like domestics, bulky lower-priced items, again, where the freight cost is significant. Some deflationary items were as much as 20% to 30% and, again, mostly freight-related," he added.

Read More

Continue Reading

Government

Walmart has really good news for shoppers (and Joe Biden)

The giant retailer joins Costco in making a statement that has political overtones, even if that’s not the intent.

Published

on

As we head toward a presidential election, the presumed candidates for both parties will look for issues that rally undecided voters. 

The economy will be a key issue, with Democrats pointing to job creation and lowering prices while Republicans will cite the layoffs at Big Tech companies, high housing prices, and of course, sticky inflation.

The covid pandemic created a perfect storm for inflation and higher prices. It became harder to get many items because people getting sick slowed down, or even stopped, production at some factories.

Related: Popular mall retailer shuts down abruptly after bankruptcy filing

It was also a period where demand increased while shipping, trucking and delivery systems were all strained or thrown out of whack. The combination led to product shortages and higher prices.

You might have gone to the grocery store and not been able to buy your favorite paper towel brand or find toilet paper at all. That happened partly because of the supply chain and partly due to increased demand, but at the end of the day, it led to higher prices, which some consumers blamed on President Joe Biden's administration.

Biden, of course, was blamed for the price increases, but as inflation has dropped and grocery prices have fallen, few companies have been up front about it. That's probably not a political choice in most cases. Instead, some companies have chosen to lower prices more slowly than they raised them.

However, two major retailers, Walmart (WMT) and Costco, have been very honest about inflation. Walmart Chief Executive Doug McMillon's most recent comments validate what Biden's administration has been saying about the state of the economy. And they contrast with the economic picture being painted by Republicans who support their presumptive nominee, Donald Trump.

Walmart has seen inflation drop in many key areas.

Image source: Joe Raedle/Getty Images

Walmart sees lower prices

McMillon does not talk about lower prices to make a political statement. He's communicating with customers and potential customers through the analysts who cover the company's quarterly-earnings calls.

During Walmart's fiscal-fourth-quarter-earnings call, McMillon was clear that prices are going down.

"I'm excited about the omnichannel net promoter score trends the team is driving. Across countries, we continue to see a customer that's resilient but looking for value. As always, we're working hard to deliver that for them, including through our rollbacks on food pricing in Walmart U.S. Those were up significantly in Q4 versus last year, following a big increase in Q3," he said.

He was specific about where the chain has seen prices go down.

"Our general merchandise prices are lower than a year ago and even two years ago in some categories, which means our customers are finding value in areas like apparel and hard lines," he said. "In food, prices are lower than a year ago in places like eggs, apples, and deli snacks, but higher in other places like asparagus and blackberries."

McMillon said that in other areas prices were still up but have been falling.

"Dry grocery and consumables categories like paper goods and cleaning supplies are up mid-single digits versus last year and high teens versus two years ago. Private-brand penetration is up in many of the countries where we operate, including the United States," he said.

Costco sees almost no inflation impact

McMillon avoided the word inflation in his comments. Costco  (COST)  Chief Financial Officer Richard Galanti, who steps down on March 15, has been very transparent on the topic.

The CFO commented on inflation during his company's fiscal-first-quarter-earnings call.

"Most recently, in the last fourth-quarter discussion, we had estimated that year-over-year inflation was in the 1% to 2% range. Our estimate for the quarter just ended, that inflation was in the 0% to 1% range," he said.

Galanti made clear that inflation (and even deflation) varied by category.

"A bigger deflation in some big and bulky items like furniture sets due to lower freight costs year over year, as well as on things like domestics, bulky lower-priced items, again, where the freight cost is significant. Some deflationary items were as much as 20% to 30% and, again, mostly freight-related," he added.

Read More

Continue Reading

Trending